<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03699657</url>
  </required_header>
  <id_info>
    <org_study_id>SNUH-2014-0279</org_study_id>
    <nct_id>NCT03699657</nct_id>
  </id_info>
  <brief_title>Dual and Single Switching Monopolar RFA Using Separable Clustered Electrode for Treatment of HCC</brief_title>
  <official_title>Radiofrequency Ablation Using a Separable Clustered Electrode for the Treatment of Hepatocellular Carcinomas: A Randomized Controlled Trial of a Dual-Switching Monopolar Mode Versus a Single-Switching Monopolar Mode</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study was conducted to prospectively compare the efficacy, safety and mid-term outcomes&#xD;
      of dual-switching monopolar (DSM) radiofrequency ablation (RFA) with those of conventional&#xD;
      single-switching monopolar (SSM) RFA in the treatment of hepatocellular carcinoma (HCC).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Recently, dual switching monopolar RFA (DSM-RFA) was developed to enhance further the&#xD;
      efficiency of the single switching monopolar RFA (SSM-RFA) in creating ablation zone; Yoon et&#xD;
      al. reported that DSM-RFA allowed significantly greater RF energy delivery to target tissue&#xD;
      per given time, and then, created significantly larger ablation zone than the SSM-RFA in ex&#xD;
      vivo and in vivo animal experiments. A retrospective comparative study by Choi et al.&#xD;
      reported that the DSM-RFA created significantly larger ablation volume than, but seemed to&#xD;
      show similar LTP rate to the SSM-RFA. Still, whether the physical differences between SSM-RFA&#xD;
      and DSM-RFA translate into better clinical outcomes remains an open question. Regarding that&#xD;
      the choice of equipment is an essential factor to consider in planning image-guided tumor&#xD;
      ablation procedure, we thought that the prospective comparison between DSM-RFA and the&#xD;
      SSM-RFA would be helpful for improving results of RFA.&#xD;
&#xD;
      Therefore, the purpose of this study was to prospectively compare the efficacy, safety and&#xD;
      mid-term outcomes of DSM-RFA with those of conventional SSM-RFA in the treatment of HCC.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 15, 2014</start_date>
  <completion_date type="Actual">June 19, 2019</completion_date>
  <primary_completion_date type="Actual">April 11, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Minimum diameter of ablative zone</measure>
    <time_frame>7 days after RFA</time_frame>
    <description>Minimum diameter of ablative zone on post-RFA CT or MRI in a mm.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Technical success rate</measure>
    <time_frame>1 month</time_frame>
    <description>Technical success on 1 month follow-up imaging after RFA (no residual/progressed tumor)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IDR rate</measure>
    <time_frame>24 months after RFA</time_frame>
    <description>Cumulative intrahepatic distant recurrence (IDR) rate over two years after RFA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EM rate</measure>
    <time_frame>24 months after RFA</time_frame>
    <description>Cumulative extrahepatic metastasis (EM) rate over two years after RFA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>1-year local tumor progression (LTP)</measure>
    <time_frame>12 months after RFA</time_frame>
    <description>Comparison of rates of LTP in two groups in a year after RFA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>2-year LTP</measure>
    <time_frame>24 months after RFA</time_frame>
    <description>Comparison of rates of LTP in two groups in two years after RFA</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Complication</measure>
    <time_frame>1 month after RFA</time_frame>
    <description>Description and comparison of the type and incidence of major complication after RFA are assessed according to Society of Interventional Radiology (SIR) grading system in two groups.</description>
  </other_outcome>
  <other_outcome>
    <measure>Volume of ablative zone</measure>
    <time_frame>7 days after RFA</time_frame>
    <description>Volume of ablative zone on post-RFA CT or MRI in a mm3.</description>
  </other_outcome>
  <other_outcome>
    <measure>Ablation time</measure>
    <time_frame>1 day</time_frame>
    <description>RFA procedure time in each patient.</description>
  </other_outcome>
  <other_outcome>
    <measure>Maximal diameter of ablative zone</measure>
    <time_frame>7 days after RFA</time_frame>
    <description>Maximal diameter of ablative zone on post-RFA CT or MRI in a mm.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">86</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <arm_group>
    <arm_group_label>RFA with DSM mode</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>RFA is performed in dual switching mode using a separable clustered electrode (Octopus®) and a three-channel dual-generator unit.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RFA with SSM mode</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>RFA is performed in single switching mode using a separable clustered electrode (Octopus®) and a three-channel dual-generator unit.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>DSM</intervention_name>
    <description>Monopolar RFA using dual switching mode (DSM)</description>
    <arm_group_label>RFA with DSM mode</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>SSM</intervention_name>
    <description>Monopolar RFA using single switching mode (SSM)</description>
    <arm_group_label>RFA with SSM mode</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Separable clustered electrodes</intervention_name>
    <description>A separable clustered electrode is similar to a clustered electrode, although it differs from a conventional clustered electrode in that each individual electrode is separable.</description>
    <arm_group_label>RFA with DSM mode</arm_group_label>
    <arm_group_label>RFA with SSM mode</arm_group_label>
    <other_name>Octopus®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosed with HCC (&gt;= 1.5cm and &lt; 5cm in maximal diameter) according to AASLD&#xD;
             guideline or LI-RADS on MDCT or liver MRI within 60 days before RFA&#xD;
&#xD;
          -  no history of previous locoregional treatment&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  more than three HCC nodules&#xD;
&#xD;
          -  tumors abutting to the central portal vein or hepatic vein with a diameter &gt; 5 mm&#xD;
&#xD;
          -  Child-Pugh class C&#xD;
&#xD;
          -  tumors with major vascular invasion&#xD;
&#xD;
          -  extrahepatic metastasis&#xD;
&#xD;
          -  severe coagulopathy (platelet cell count of less than 50,000 cells/mm3 or INR&#xD;
             prolongation of more than 50 %)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeong Min Lee, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>October 5, 2018</study_first_submitted>
  <study_first_submitted_qc>October 5, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 9, 2018</study_first_posted>
  <last_update_submitted>March 18, 2020</last_update_submitted>
  <last_update_submitted_qc>March 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul National University Hospital</investigator_affiliation>
    <investigator_full_name>Jeong Min Lee</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>RFA</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

